|
1
|
Lyon AR, Sato M, Hajjar RJ, Samulski RJ
and Harding SE: Gene therapy: targeting the myocardium. Heart.
94:89–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marshall E: Gene therapy death prompts
review of adenovirus vector. Science. 286:2244–2245. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Faurez F, Dory D, Le Moigne V, Gravier R
and Jestin A: Biosafety of DNA vaccines: new generation of DNA
vectors and current knowledge on the fate of plasmids after
injection. Vaccine. 28:3888–3895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ginn SL, Alexander IE, Edelstein ML, Abedi
MR and Wixon J: Gene therapy clinical trials worldwide to 2012 - an
update. J Gene Med. 15:65–77. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jechlinger W: Optimization and delivery of
plasmid DNA for vaccination. Expert Rev Vaccines. 5:803–825. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang M, Chen Z, Hu S, et al: Novel
minicircle vector for gene therapy in murine myocardial infarction.
Circulation. 120(Suppl 11): S230–S237. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen ZY, He CY, Ehrhardt A and Kay MA:
Minicircle DNA vectors devoid of bacterial DNA result in persistent
and high-level transgene expression in vivo. Mol Ther. 8:495–500.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen ZY, He CY, Meuse L and Kay MA:
Silencing of episomal transgene expression by plasmid bacterial DNA
elements in vivo. Gene Ther. 11:856–864. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen ZY, He CY and Kay MA: Improved
production and purification of minicircle DNA vector free of
plasmid bacterial sequences and capable of persistent transgene
expression in vivo. Hum Gene Ther. 16:126–131. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia F, Wilson KD, Sun N, et al: A nonviral
minicircle vector for deriving human iPS cells. Nat Methods.
7:197–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang C, Gao S, Jiang W, et al: Targeted
minicircle DNA delivery using folate-poly(ethylene
glycol)-polyethylenimine as non-viral carrier. Biomaterials.
31:6075–6086. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dietz WM, Skinner NE, Hamilton SE, et al:
Minicircle DNA is superior to plasmid DNA in eliciting
antigen-specific CD8+ T-cell responses. Mol Ther.
21:1526–1535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hine CM, Seluanov A and Gorbunova V: Use
of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl
Acad Sci USA. 105:20810–20815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cohen JI: Epstein-Barr virus infection. N
Engl J Med. 343:481–492. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bochkarev A, Barwell JA, Pfuetzner RA,
Bochkareva E, Frappier L and Edwards AM: Crystal structure of the
DNA-binding domain of the Epstein-Barr virus origin-binding
protein, EBNA1, bound to DNA. Cell. 84:791–800. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niedobitek G, Agathanggelou A and Nicholls
JM: Epstein-Barr virus infection and the pathogenesis of
nasopharyngeal carcinoma: viral gene expression, tumour cell
phenotype, and the role of the lymphoid stroma. Semin Cancer Biol.
7:165–174. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Altmann M, Pich D, Ruiss R, Wang J, Sugden
B and Hammerschmidt W: Transcriptional activation by EBV nuclear
antigen 1 is essential for the expression of EBV’s transforming
genes. Proc Natl Acad Sci USA. 103:14188–14193. 2006.
|
|
18
|
Leight ER and Sugden B: EBNA-1: a protein
pivotal to latent infection by Epstein-Barr virus. Rev Med Virol.
10:83–100. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lindner SE and Sugden B: The plasmid
replicon of Epstein-Barr virus: mechanistic insights into
efficient, licensed, extrachromosomal replication in human cells.
Plasmid. 58:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li JH, Chia M, Shi W, et al:
Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer
Res. 62:171–178. 2002.PubMed/NCBI
|
|
21
|
Zuo Y, Wu J, Xu Z, et al:
Minicircle-oriP-IFNγ: a novel targeted gene therapeutic system for
EBV positive human nasopharyngeal carcinoma. PLoS One.
6:e194072011.
|
|
22
|
Kay MA, He CY and Chen ZY: A robust system
for production of minicircle DNA vectors. Nat Biotechnol.
28:1287–1289. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teng ZP, Ooka T, Huang DP and Zeng Y:
Detection of Epstein-Barr virus DNA in well and poorly
differentiated nasopharyngeal carcinoma cell lines. Virus Genes.
13:53–60. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu T, Ding Y, Xie W, et al: An imageable
metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer
Res. 13:3960–3967. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheung ST, Huang DP, Hui AB, et al:
Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring
Epstein-Barr virus. Int J Cancer. 83:121–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong Y, Aied A, Li J, Wang Q, Hu X and
Wang W: An in vitro approach for production of non-scar minicircle
DNA vectors. J Biotechnol. 166:84–87. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Manjila SB, Baby JN, Bijin EN, Constantine
I, Pramod K and Valsalakumari J: Novel gene delivery systems. Int J
Pharm Investig. 3:1–7. 2013. View Article : Google Scholar
|
|
28
|
Gao L, Xie L, Long X, et al: Efficacy of
MRI visible iron oxide nanoparticles in delivering minicircle DNA
into liver via intra-biliary infusion. Biomaterials. 34:3688–3696.
2013. View Article : Google Scholar : PubMed/NCBI
|
